Johnson & Johnson Announces Collaboration with the Beth Israel Deaconess Medical Center to Accelerate COVID-19 Vaccine Development

NEW BRUNSWICK, N.J., March 13, 2020 -- Johnson & Johnson today announced that its Janssen Pharmaceutical Companies have entered a collaboration with the Beth Israel Deaconess Medical Center (BIDMC

Latest News Clinical News 5
Read All

Update on Phase III GY004 Trial for Cediranib Added to Lynparza in Platinum-Sensitive Relapsed Ovarian Cancer

12 March 2020 -- AstraZeneca and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) today announced high-level results from the Phase III GY004 trial, led by

Latest News Clinical News 18
Read All

New Clinical Study Data for Gilead’s Investigational HIV-1 Capsid Inhibitor GS-6207 Presented at CROI 2020

BOSTON--(BUSINESS WIRE) March 11, 2020 -- Gilead Sciences, Inc. (NASDAQ: GILD) today announced data from clinical and preclinical studies exploring the use of GS-6207, an investigational, novel, first

Latest News Clinical News 18
Read All

Treatment With Gilead’s Vesatolimod Is Evaluated for Safety and Virologic and Immunologic Response Versus Placebo in Phase 1B HIV Functional Cure Study

BOSTON--(BUSINESS WIRE) March 10, 2020 -- Gilead Sciences, Inc. (Nasdaq: GILD) today announced results from a Phase 1b trial evaluating the company’s investigational toll-like receptor 7 (TLR7) agonis

Latest News Clinical News 21
Read All

Janssen Announces U.S. FDA Breakthrough Therapy Designation Granted for JNJ-6372 for the Treatment of Non-Small Cell Lung Cancer

RARITAN, NJ, March 10, 2020 -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designati

Latest News Clinical News 19
Read All

CytoDyn Files IND and Protocol for Phase 2 Clinical Trial for Treatment of Coronavirus Patients with Leronlimab (PRO 140)

VANCOUVER, Washington, March 09, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 ant

Latest News Clinical News 38
Read All

Kala Pharmaceuticals Announces Statistically Significant Results for Primary and Key Secondary Endpoints in STRIDE 3 Clinical Trial Evaluating EYSUVIS™ for Signs and Symptoms of Dry Eye Disease

WATERTOWN, Mass.--(BUSINESS WIRE) -- Kala Pharmaceuticals, Inc. (Kala) (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies fo

Latest News Clinical News 38
Read All

AbbVie Partnering with Global Authorities to Determine Efficacy of HIV Drug in Treating COVID-19

NORTH CHICAGO, Ill., March 9, 2020 /PRNewswire/ -- AbbVie (NYSE:ABBV) today confirmed the company's activities in the fight to address the COVID-19 public health crisis, including supporting the e

Latest News Clinical News 31
Read All

Janssen Announces Results of Phase 3 Study Demonstrating the Safety and Efficacy of Long-Acting Injectable HIV Treatment Regimen of Rilpivirine And Cabotegravir through 96 Weeks

CORK, IRELAND, March 9, 2020 -- The Janssen Pharmaceutical Companies of Johnson & Johnson presented new data from the global Phase 3 trial today for the novel, investigational, long-acting (LA), t

Latest News Clinical News 42
Read All

Janssen Announces 48-week Results of Phase 3b Study Demonstrating the Safety and Efficacy of Long-Acting Injectable HIV Treatment of Rilpivirine and Cabotegravir Administered Every Two Months

CORK, IRELAND, March 9, 2020 -- The Janssen Pharmaceutical Companies of Johnson & Johnson presented new data from its global Phase 3b trial today for the novel, investigational, long-acting (LA),

Latest News Clinical News 63
Read All

Update on Phase III DANUBE Trial for Imfinzi and Tremelimumab in Unresectable, Stage IV Bladder Cancer

6 March 2020 -- The Phase III DANUBE trial for Imfinzi (durvalumab) and Imfinzi plus tremelimumab in unresectable, Stage IV (metastatic) bladder cancer did not meet the primary endpoints of improving

Latest News Clinical News 59
Read All

Orexo Submits Application for Vorvida® to the FDA to Enable Commercialization in the US

Uppsala, Sweden – March 6, 2020. -- Orexo AB (publ), today announces it has submitted an application to the US Food and Drug Administration (FDA) for vorvida® to enable commercialization in the US. vo

Latest News Clinical News 47
Read All
News
- CLINIEXPERT -
Int'l Clinical Service Expert

We are the leader
Because of our professionism